Medtronic's (NYSE: MDT) primary catalyst as mid-year approaches is that headwinds are not impairing results as much as feared. Rising costs, margin compression, and general uncertainty linked to macroeconomic headwinds were reflected in the company's June 3 earnings results, but the results were inherently strong and expected to remain so.
The impact on share prices will be a rise, as the market is deeply oversold and ripe for a rebound. The only question is how high the stock price might go, and the signs suggest a 25% upside is easy.
